Outpatient Intravenous Remdesivir to Prevent Progression to Severe COVID-19: An Observational Study from a Greek Hospital

Abstract

Background: Remdesivir, a viral RNA polymerase inhibitor, has been a powerful weapon in the battle against the SARS-CoV-2 pandemic. Originally approved for use in hospitalized patients, remdesivir improves clinical outcomes in patients with moderate to severe coronavirus disease 2019 (COVID-19). After proving efficacious in hospitalized patients, its use was approved in early disease for symptomatic, non-hospitalized patients that present risk factors for progression to severe disease. Methods: We conducted an observational clinical trial involving 107 non-hospitalized COVID-19 patients who attended the emergency department of a third-level greek hospital seeking care for symptoms appearing within the previous 5 days and who had at least one risk factor for progression to severe disease. After arterial blood gas evaluation, eligible patients received intravenous remdesivir at a dose of 200 mg on day 1 and 100 mg on days 2 and 3. The efficacy endpoint was set as COVID-19-related hospitalization or death in the next 14 days. Results: A total of 107 patients (57.0% men) participated in the study, 51 (47.7%) of them fully vaccinated. Most prevalent were age ≥ 60 years old, cardiovascular/cerebrovascular disease, immunosuppression or malignancy, obesity, diabetes mellitus, and chronic lung disease. All patients enrolled completed the 3-day course, with a total of 3 out of 107 patients (2.8%) eventually having a COVID-19-related hospitalization by day 14, while no deaths were reported by day 14. Conclusion: Among non-hospitalized patients with at least one risk factor for progression to severe COVID-19, a 3-day course of intravenous remdesivir yielded favourable results.

Early 3‑day course of remdesivir for the prevention of the progression to severe COVID‑19 in the elderly: A single‑centre, real‑life cohort study

“…Currently, a limited number of real-life studies have demonstrated that the early administration of remdesivir has a good safety profile and significantly reduces the risk of COVID-19 disease progression and mortality among high-risk patients in the era of the omicron variant ( 14 , 16-18 ). A recent study focused on non-hospitalized vaccinated high-risk patients and demonstrated that a 3-day course of remdesivir resulted in a 75% lower possibility of hospitalization and 95% of respiratory failure, with favourable outcomes in cases that required hospitalization ( 19 ).…”

“…Apart from pivotal studies, limited real-world data supporting the effectiveness of early remdesivir therapy in decreasing the overall risk of hospitalization and disease progression in SARS-CoV-2 high-risk outpatients are currently available ( 14 , 15 ). In addition, real-life data focusing on the safety and effectiveness of early remdesivir among the elderly are limited.…”